# Young Women Face Near-Zero Cervical Cancer Risk After HPV Vaccination
Girls vaccinated against human papillomavirus during their school years experience nearly eliminated risk of cervical cancer death, new research confirms. The finding represents a major public health victory since the HPV vaccine rollout began in the UK in 2008.
The study tracked outcomes for women who received the jab as adolescents and found cervical cancer mortality in this cohort dropped to near zero. Hundreds of lives have been spared since vaccination programs began targeting school-age girls over a decade ago.
Human papillomavirus causes the vast majority of cervical cancers. The vaccine protects against the most dangerous strains responsible for approximately 70 percent of cases. When administered before sexual activity begins, the shot produces robust immunity.
The UK's decision to vaccinate girls starting at age 12 or 13 has proven exceptionally effective. Coverage rates in the country exceed 80 percent among eligible age groups. Countries with similar vaccination programs report comparable reductions in cervical cancer incidence and death rates.
Cervical cancer kills roughly 260 women annually in the UK. The new data suggests this number will decline further as successive cohorts of vaccinated women age. Early screening programs, which detect precancerous changes through smear tests, continue providing an additional safety net for women already infected with HPV.
The research underscores why public health organizations recommend routine HPV vaccination for all adolescents. The American Academy of Pediatrics and CDC endorse vaccination for ages 11 to 12, with catch-up shots available through age 26.
For young women already vaccinated, screening programs remain important since no vaccine offers 100 percent protection. Those unvaccinated should discuss catch-up vaccination with their healthcare provider. The combination of vaccination and regular screening creates powerful defense against a once-common